Oncolys BioPharma Inc.
Notice Regarding Issuance of New Shares as Restricted Stock Compensation
Resolved to apply a restricted stock compensation plan through issuance of new shares. 17,700 shares to be issued at an issue price of 7,550 yen, total amount 133,635,000 yen, allocated to employees and directors. Restriction periods up to 5 years; detailed conditions for lifting restrictions upon expiration are specified.
Key Figures
- Key figure 1: Number of shares to be issued 17,700 shares
- Key figure 2: Total issue amount 133,635,000 yen
- Key figure 3: Issue price 7,550 yen
AI要約
Overview
At today's board meeting, the board resolved to issue new shares as restricted stock compensation. The shares to be issued are 17,700 ordinary shares, the issue price is 7,550 yen per share, and the total amount is 133,635,000 yen. Allocations will be made to three internal directors and 20 employees, and payment will be made on the premise of concluding restricted stock allocation agreements specifying the terms. The restriction periods are set based on 2026/11/24–2028/11/30 (example for internal directors) and for employees similarly based on 2026/11/24–2028/11/30.
Impact on Shareholders and Future Outlook
The purpose of the stock compensation plan is to strengthen incentives to contribute to share price appreciation and corporate value enhancement. During the restriction period, disposition such as transfer of the shares is restricted, and restrictions will be lifted if conditions are met at the time of expiration. Special conditions for corporate reorganizations and the like are also stipulated, aiming to motivate performance-linked behavior through long-term incentive design.
Oncolys BioPharma Inc.
Company overview · Stock price · Financial data · All IR
